|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | 0.00% |
|
-50.00% | -66.67% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-30 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 671K 475K 418K 390K 358K 45.58M 682K 4.61M 1.8M 22.55M 1.79M 1.75M 77.95M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.17M 1.54M 1.35M 1.26M 1.16M 148M 2.21M 14.91M 5.83M 72.98M 5.78M 5.66M 252M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -50.00% | ||
| 1 month | -50.00% | ||
| 3 months | -66.67% | ||
| 6 months | -66.67% | ||
| Current year | -66.67% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 20/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 20/12/2016 |
David Kideckel
CHM | Chairman | - | 27/02/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/10/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 03/05/24 | Other | Director | 0 | 0% | ||
| 03/05/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -50.00% | -50.00% | -85.71% | 476K | |
| +4.64% | +6.98% | +24.96% | +119.35% | 99.52B | |
| +1.38% | +2.99% | +47.96% | +151.55% | 53.72B | |
| +1.40% | -1.02% | +2.11% | +271.79% | 23.01B | |
| -0.06% | -2.78% | -13.33% | -19.68% | 8.19B | |
| +0.21% | -7.75% | -32.34% | -35.45% | 7.47B | |
| +0.47% | -2.10% | -10.71% | -29.59% | 6.83B | |
| +0.77% | -1.08% | +19.94% | +27.50% | 6.14B | |
| +0.92% | -1.62% | +0.29% | +22.92% | 5.31B | |
| -1.18% | -2.90% | -6.86% | -8.24% | 3.74B | |
| Average | +0.86% | -1.42% | -1.80% | +41.44% | 21.39B | |
| Weighted average by Cap. | +2.70% | +0.69% | +22.36% | +121.09% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -562K -494K -461K -423K -53.88M -807K -5.44M -2.13M -26.66M -2.11M -2.07M -92.15M | -383K -272K -239K -223K -205K -26.04M -390K -2.63M -1.03M -12.88M -1.02M -998K -44.53M |
| Net Debt | 1.27M 902K 793K 740K 680K 86.53M 1.3M 8.74M 3.42M 42.81M 3.39M 3.32M 148M | 1.5M 1.06M 935K 872K 801K 102M 1.53M 10.3M 4.03M 50.43M 4M 3.91M 174M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
